Press Releases and Blog
Blog
The Wall Street Journal Editorial Board: “You Have To Smile At Ms. Khan Portraying Big Drug Makers As Victims In Her Suit.”
In case you missed it, The Wall Street Journal Editorial Board warns the Federal Trade Commission’s (FTC) recent enforcement action against pharmacy benefit managers (PBMs) would lead
PBMs Commit To Continued GLP-1 Coverage Options; Pharma Companies Won’t Commit To Setting Lower List Prices
The U.S. Senate Committee on Health, Education, Labor & Pensions (HELP) held a hearing, “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High
Amid IRA Implementation, PBMs Continue to Deliver Value and Savings for Medicare Beneficiaries
By Tim Dube, SVP, Policy and Regulatory Insights It’s been two years since President Biden signed the Inflation Reduction Act (IRA) into law, whose several
House Judiciary Witnesses From Academia Highlight Critical Role PBMs Play
This week, the U.S. House Committee on the Judiciary Subcommittee on the Administrative State, Regulatory Reform, and Antitrust held a hearing on pharmacy benefit managers
ICYMI: Ryan Costello Urges Congress To Pass Patent Abuse Legislation Over Misguided Proposals Targeting PBMs
In case you missed it, Ryan Costello, former U.S. Representative (R-PA-06), urged Members of Congress to focus on solutions to stop Big Pharma’s patent abuse
ICYMI: Senate Judiciary Committee Got It Right on Big Pharma’s Patent Abuse As Root Cause Of High Rx Prices
The U.S. Senate Committee on the Judiciary held a hearing earlier this summer, “Ensuring Affordable & Accessible Medications: Examining Competition in the Prescription Drug Market.”
Press Releases
PCMA Statement On House Judiciary Subcommittee Hearing
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the U.S. House Committee on the Judiciary Subcommittee on the Administrative
RxBenefits Joins Pharmaceutical Care Management Association
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that RxBenefits is joining the trade association as its newest member. “PCMA is proud
PCMA Statement On Biden Administration’s Medicare Negotiated Drug Prices
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement following the Biden Administration’s announcement of the first ten Medicare negotiated drug
PCMA Statement on House Oversight Hearing
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead of the U.S. House Committee on Oversight and Accountability hearing, “The Role
Cornyn-Blumenthal Legislation Would Encourage More Generic and Biosimilar Competition in the Prescription Drug Market to Help Lower Costs for Patients
(Washington, D.C.) — The Pharmaceutical Care Management Association released the following statement today following the U.S. Senate’s passage of legislation sponsored by Senators John Cornyn
PCMA Statement on FTC Interim PBM Report
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Federal Trade Commission (FTC) interim report
ICYMI: RealClearHealth: JC Scott: Let’s Get Drug Pricing Legislation Right
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), highlights the opportunity Congress now has to get
Patient Access and Insulin: Market Forces, Innovative PBM Programs Lowering Costs for Patients
The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined by just three drug companies
Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO
Economists Ike Brannon and Anthony Lo Sasso: The Real Challenge Facing Independent Pharmacies
As independent pharmacies conduct a “Fly-In” in Washington D.C this week, they will undoubtedly double-down on support for policies targeting pharmacy benefit companies that would
What They Are Saying: PBMs Help Businesses, Families, And Patients Save On Rx Costs, Allow Employers To Offer Competitive Benefits
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically
Pharmacy Benefit Companies Partner To Support Rural Pharmacies And Patients
This week, community pharmacists will conduct a “Fly-In” in Washington D.C. Undoubtedly, part of the message to Congress will be critical of pharmacy benefit companies,
RealClearMarkets Op-Ed: “Attacks On Pharmacy Benefit Managers Won’t Reduce Drug Prices”
As Congress returns to Washington, Ike Brannon, senior fellow at the Jack Kemp Foundation, explains how state and federal efforts to undermine the role of
PBMs Support Competition and Innovation to Lower Prescription Drug Costs
The pharmacy benefit company market is competitive and diverse, with more than 70 full-service PBMs of varying size operating across the country. These companies differentiate themselves through the
Matrix Global Advisors Touts Biosimilar Interchangeability Proposal in Biden Administration Budget – SSR Health: Biosimilar Competition Leads to Significant Decline in Net Prices on Brand Humira
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake
ICYMI: RealClearHealth: Pat Toomey: Attacking PBMs Won’t Solve President Biden’s Inflation Problem
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting
